HK1243435A1 - 改良的april結合抗體 - Google Patents

改良的april結合抗體

Info

Publication number
HK1243435A1
HK1243435A1 HK18102920.1A HK18102920A HK1243435A1 HK 1243435 A1 HK1243435 A1 HK 1243435A1 HK 18102920 A HK18102920 A HK 18102920A HK 1243435 A1 HK1243435 A1 HK 1243435A1
Authority
HK
Hong Kong
Prior art keywords
binding antibodies
april binding
altered
altered april
antibodies
Prior art date
Application number
HK18102920.1A
Other languages
English (en)
Inventor
H．范伊訥恩納姆
A．范埃爾莎
J．P．美狄亞
D．盧特杰胡思可
Original Assignee
艾杜羅生物科技歐洲控股有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 艾杜羅生物科技歐洲控股有限責任公司 filed Critical 艾杜羅生物科技歐洲控股有限責任公司
Publication of HK1243435A1 publication Critical patent/HK1243435A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
HK18102920.1A 2015-01-09 2018-02-28 改良的april結合抗體 HK1243435A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2014108A NL2014108B1 (en) 2015-01-09 2015-01-09 Altered april binding antibodies.
PCT/EP2016/050314 WO2016110587A1 (en) 2015-01-09 2016-01-08 Altered april binding antibodies

Publications (1)

Publication Number Publication Date
HK1243435A1 true HK1243435A1 (zh) 2018-07-13

Family

ID=53783809

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18102920.1A HK1243435A1 (zh) 2015-01-09 2018-02-28 改良的april結合抗體

Country Status (20)

Country Link
US (4) US9969808B2 (zh)
EP (2) EP3242892B1 (zh)
JP (2) JP6824190B2 (zh)
KR (2) KR102612373B1 (zh)
CN (1) CN107207602B (zh)
AU (1) AU2016205977B2 (zh)
BR (1) BR112017014771A2 (zh)
CA (1) CA2973286A1 (zh)
DK (1) DK3242892T3 (zh)
EA (1) EA201791270A1 (zh)
ES (1) ES2902901T3 (zh)
HK (1) HK1243435A1 (zh)
IL (1) IL253306B (zh)
MA (1) MA41313A (zh)
MX (2) MX2017009052A (zh)
NL (1) NL2014108B1 (zh)
PL (1) PL3242892T3 (zh)
SG (1) SG11201705589UA (zh)
WO (1) WO2016110587A1 (zh)
ZA (2) ZA201704920B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
CN118027201A (zh) 2015-11-25 2024-05-14 威特拉公司 April的抗体分子及其应用
AU2016369519B2 (en) 2015-12-16 2023-04-20 Gritstone Bio, Inc. Neoantigen identification, manufacture, and use
AU2018289493A1 (en) * 2017-06-20 2019-12-12 Dana-Farber Cancer Institute, Inc. Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
US20200190163A1 (en) * 2018-10-26 2020-06-18 Lijun Wu Humanized bcma-car-t cells
WO2020144535A1 (en) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Methods and compositions for treatment of multiple myeloma
US20240132598A1 (en) * 2019-10-15 2024-04-25 Dragonfly Therapeutics, Inc. Antibodies targeting flt3 and use thereof
US20240117054A1 (en) * 2019-10-15 2024-04-11 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and flt3
CA3161516A1 (en) 2019-12-17 2021-06-24 Philip Thomas FROHLICH Methods of treating iga nephropathy with atrasentan
EP4157339A1 (en) * 2020-05-29 2023-04-05 Chinook Therapeutics, Inc. Methods of treating iga nephropathy with an april binding antibody
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022236335A1 (en) 2021-05-07 2022-11-10 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
TW202400637A (zh) 2022-04-25 2024-01-01 美商威特拉公司 April之抗體分子及其用途
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein
WO2024092240A1 (en) 2022-10-28 2024-05-02 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US778A (en) 1838-06-12 Thomas wright
US4946A (en) 1847-01-26 Improvement in carriage-wheels
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD272023A3 (de) 1985-12-04 1989-09-27 Ilmenau Tech Hochschule Vorrichtung, insbesondere zur praezisionslichtstrahlablenkung
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
KR100507431B1 (ko) 1994-11-07 2005-12-21 휴먼 게놈 사이언시즈, 인코포레이티드 종양괴사인자-γ
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
CZ294615B6 (cs) 1997-09-12 2005-02-16 Apotech R & D Sa Léčivo obsahující protilátky reaktivní s polypeptidovým ligandem APRIL pro léčení rakoviny
ES2267593T3 (es) * 2000-02-16 2007-03-16 Genentech, Inc. Anticuerpos anti-april y celulas hibridomas.
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
JP2004537290A (ja) 2001-05-24 2004-12-16 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体
WO2003086310A2 (en) 2002-04-12 2003-10-23 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
WO2005120571A2 (en) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
UY30776A1 (es) * 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN102171247A (zh) * 2008-07-02 2011-08-31 特鲁比昂药品公司 TNF-α拮抗剂多靶点结合蛋白
EP2321351B1 (en) * 2008-08-18 2017-11-01 Pfizer Inc. Antibodies to ccr2
AU2009294416B2 (en) * 2008-09-19 2014-05-22 Medimmune Llc Antibodies against sonic hedgehog homolog and uses thereof
EP4147719A1 (en) * 2009-03-02 2023-03-15 Aduro Biotech Holdings, Europe B.V. Antibodies against a proliferating inducing ligand (april)
CN101928345B (zh) * 2010-06-21 2012-08-29 中国科学技术大学 一种人源化抗体及其人源化改造方法
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
CN118027201A (zh) * 2015-11-25 2024-05-14 威特拉公司 April的抗体分子及其应用

Also Published As

Publication number Publication date
CA2973286A1 (en) 2016-07-14
PL3242892T3 (pl) 2022-02-21
JP2018502918A (ja) 2018-02-01
US10377830B2 (en) 2019-08-13
CN107207602B (zh) 2021-05-25
IL253306B (en) 2021-06-30
JP7060728B2 (ja) 2022-04-26
US10961316B2 (en) 2021-03-30
US20200079859A1 (en) 2020-03-12
US20210221900A1 (en) 2021-07-22
AU2016205977A1 (en) 2017-08-31
KR20230170120A (ko) 2023-12-18
MX2022007774A (es) 2022-08-10
EP4029879A1 (en) 2022-07-20
KR20170099992A (ko) 2017-09-01
JP2021072801A (ja) 2021-05-13
NL2014108A (en) 2016-09-23
US9969808B2 (en) 2018-05-15
US20160264674A1 (en) 2016-09-15
ZA201704920B (en) 2018-11-28
NL2014108B1 (en) 2016-09-30
SG11201705589UA (en) 2017-08-30
EA201791270A1 (ru) 2017-12-29
ZA201804317B (en) 2019-09-25
MA41313A (fr) 2021-05-12
MX2017009052A (es) 2018-04-11
EP3242892A1 (en) 2017-11-15
IL253306A0 (en) 2017-09-28
US20180258176A1 (en) 2018-09-13
JP6824190B2 (ja) 2021-02-03
EP3242892B1 (en) 2021-10-20
AU2016205977B2 (en) 2021-11-04
WO2016110587A1 (en) 2016-07-14
KR102612373B1 (ko) 2023-12-13
DK3242892T3 (da) 2022-01-24
BR112017014771A2 (pt) 2018-01-23
CN107207602A (zh) 2017-09-26
ES2902901T3 (es) 2022-03-30

Similar Documents

Publication Publication Date Title
HK1253507A1 (zh) 抗 ror1 抗體
HK1254836A1 (zh) 抗-ror1抗體
HK1256116A1 (zh) 抗lag-3抗體
ZA201804317B (en) Altered april binding antibodies
GB201521393D0 (en) Antibodies
GB201521391D0 (en) Antibodies
HK1246804A1 (zh) Tau結合抗體
IL253633A0 (en) Anti-transthyretin antibodies
GB201521382D0 (en) Antibodies
IL255323A0 (en) Anti-fcrn antibodies
HK1255056A1 (zh) 抗cd115抗體
SG11201706125QA (en) Anti-transthyretin antibodies
SG11201706126WA (en) Anti-transthyretin antibodies
GB201509907D0 (en) Antibodies
GB201522394D0 (en) Antibodies
GB201503438D0 (en) Antibodies
IL284022A (en) Anti-transthyretin antibodies
GB201518728D0 (en) Antibodies
GB201515572D0 (en) Anti-LAG-3 antibodies
GB201515570D0 (en) Anti-LAG-3 antibodies
GB201514425D0 (en) Antibodies
GB201508437D0 (en) Antibodies
GB201508444D0 (en) Antibodies
GB201507541D0 (en) Antibodies
GB201502591D0 (en) Antibodies